Form 8-K - Current report:
SEC Accession No. 0000950170-24-126382
Filing Date
2024-11-13
Accepted
2024-11-13 16:30:10
Documents
13
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-20241113.htm   iXBRL 8-K 43122
2 EX-99.1 stro-ex99_1.htm EX-99.1 194274
3 GRAPHIC img217863751_0.jpg GRAPHIC 5459
  Complete submission text file 0000950170-24-126382.txt   372121

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stro-20241113.xsd EX-101.SCH 26372
15 EXTRACTED XBRL INSTANCE DOCUMENT stro-20241113_htm.xml XML 4527
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 241454826
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)